



# PROTECTING PATIENTS STARTS WITH A STRONG RECOMMENDATION FROM YOU

## WHAT YOU SAY MATTERS

To communicate the importance of vaccination with SHINGRIX, follow a simple 3-step plan:

### 1 EDUCATE PATIENTS ON SHINGLES

Explain that shingles is a painful, blistering rash that can last 7-10 days and may lead to further complications.<sup>1,2,\*</sup> Starting at 50 years old, shingles risk sharply increases.<sup>2</sup>

### 2 MAKE THE RISK OF SHINGLES RELATABLE

Personalize your recommendation by using pronouns such as “you” along with connecting to the patient’s age group. Share an experience of the impact shingles has had on your patients and the importance of vaccination.

### 3 RECOMMEND SHINGRIX

Use actionable language to round out the recommendation, so it’s clear to the patient your recommendation is coming from a place of protection.

Set expectations by outlining potential vaccine side effects and creating a plan to get vaccinated.

---

**Your strong recommendation can positively influence  
your patients’ shingles vaccination decision.<sup>3</sup>**

\*SHINGRIX is not indicated for the prevention of herpes zoster-related complications.<sup>4</sup>

#### Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older. SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

#### Important Safety Information

• SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

**Please see additional Important Safety Information for SHINGRIX on other side and accompanying full Prescribing Information.**

# ESTABLISH A PLAN WITH YOUR PATIENT TO VACCINATE WITH SHINGRIX

## FOR PATIENTS 50-64 YEARS OLD:

the best time to vaccinate is during their office visit

- According to the Centers for Disease Control and Prevention, when patients receive a vaccine recommendation and are offered the vaccine at the same time, they are more likely to get vaccinated<sup>5</sup>

## FOR PATIENTS ≥65 YEARS OLD:

talk to your patients about SHINGRIX when discussing other health considerations

- Provide a prescription for SHINGRIX
- Have your staff help patients schedule their SHINGRIX vaccine at their pharmacy by using the Vaccine Scheduler at [ScheduleShingrix.com](https://www.scheduleshingrix.com)

## SHINGRIX IS \$0 FOR MOST PATIENTS ≥50 YEARS OLD<sup>6,7,†</sup>

For your patients with commercial insurance plans<sup>‡</sup>:

- 98% of commercial patients pay \$0 for SHINGRIX<sup>6</sup>
- Average copays are just \$4 or less<sup>6</sup>

For your Medicare Part D patients:

- Great coverage is now even better. All Medicare Part D patients can now get SHINGRIX for \$0 through their pharmacy<sup>7</sup>

<sup>†</sup>Coverage and cost may vary and are subject to change without notice. Reimbursement decisions are made by individual insurance plan.<sup>6</sup>

<sup>‡</sup>Based on IQVIA data of paid 2023 SHINGRIX claims.<sup>6</sup>

## Important Safety Information (cont'd)

- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

**Please see additional Important Safety Information for SHINGRIX on other side and accompanying full Prescribing Information.**

**References:** **1.** Shingles (herpes zoster): signs and symptoms. Centers for Disease Control and Prevention. Accessed February 26, 2024. [www.cdc.gov/shingles/about/symptoms.html](https://www.cdc.gov/shingles/about/symptoms.html) **2.** Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* 2008;57(RR-5):1-30. **3.** Standards for adult immunization practice. Centers for Disease Control and Prevention. May 2, 2016. Accessed February 23, 2024. [www.cdc.gov/vaccines/hcp/adults/for-practice/standards/index.html](https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/index.html) **4.** Prescribing Information for SHINGRIX. **5.** Standards for practice: vaccine administration & referral. Centers for Disease Control and Prevention. May 2, 2016. Accessed February 26, 2024. [www.cdc.gov/vaccines/hcp/adults/for-practice/standards/referral.html](https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/referral.html) **6.** Data on file, GSK. **7.** Kirchoff SM. Selected Health Provisions of the Inflation Reduction Act. Congressional Research Service. 2022;1-3. Accessed February 24, 2024. [crsreports.congress.gov/product/pdf/IF/IF12203](https://crsreports.congress.gov/product/pdf/IF/IF12203)

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK or licensor.  
SGXLBND240001 March 2024  
Produced in USA. 0002-0029-14



**SHINGRIX**  
(ZOSTER VACCINE  
RECOMBINANT, ADJUVANTED)

